	US 12,351,650 B2
	Antibodies binding to fibroblast activation protein alpha and death receptor 4
Bart E.C.G. De Goeij, Maarssen (NL); Ilse Jongerius, De Bilt (NL); Grietje Andringa, Utrecht (NL); Madelon Paauwe, The Hague (NL); Theodorus Sjouke Plantinga, Duiven (NL); David Satijn, Nieuwegein (NL); Jamila Laoukili, Zeist (NL); Onno Wouter Kranenburg, Zeist (NL); and Marije Overdijk, Utrecht (NL)
Assigned to GENMAB A/S, Valby (DK)
Filed by GENMAB A/S, Valby (DK)
Filed on Jun. 26, 2024, as Appl. No. 18/755,457.
Claims priority of application No. 23182845 (EP), filed on Jun. 30, 2023.
Prior Publication US 2025/0002610 A1, Jan. 2, 2025
Int. Cl. A61P 35/04 (2006.01); C07K 16/46 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/468 (2013.01) [A61P 35/04 (2018.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); G01N 2800/32 (2013.01)]

34 Claims

1. A bispecific antibody comprising at least

(i) a fibroblast activation protein alpha (FAPα) binding region comprising a heavy chain variable (VH) region and a light chain variable (VL) region, and

(ii) a death receptor 4 (DR4) binding region comprising a VH region and a VL region,

wherein the VH region of the FAPα binding region comprises the three complementarity determining regions, CDR1, CDR2, and CDR3, present within the amino acid sequence set forth in SEQ ID NO: 13, and the VL region of the FAPα binding region comprises the three complementarity determining regions, CDR1, CDR2, and CDR3, present within the amino acid sequence set forth in SEQ ID NO: 14.